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Patterns of genomic loss of heterozygosity predict homologous
recombination repair defects in epithelial ovarian cancer
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R Broaddus6, KH Lu7, J Chen1, TV Tran1, D Williams1, D Iliev1, S Jammulapati1, LM FitzGerald1, T Krivak8,
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BACKGROUND: Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic
relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association
between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).
METHODS: Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH
profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were
performed on 57 cancer cell lines.
RESULTS: Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or
BRCA2 (P ¼ 10  11). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed
in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data
sets (P ¼ 10  5 and 10  29), and identified breast and pancreatic cell lines with BRCA defects.
CONCLUSION: The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism.
This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.
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Hereditary and somatic defects in genes that support homologous
recombination (HR) have been implicated in predisposition to a
variety of cancers, particularly those affecting breast and ovarian
epithelium. The BRCA1 and BRCA2 genes are integral members of
the HR pathway, are required for functional HR and when
disrupted are associated with predisposition to a variety of human
cancers (Venkitaraman, 2002). BRCA1 or BRCA2 mutations and
other HR defects, have potential therapeutic relevance when used
to support agents that introduce or exploit double-stranded DNA
breaks. For example, better outcomes have been observed in
patients with BRCA1 or BRCA2 mutations following treatment with
DNA-damaging agents such as platinum salts (Tan et al, 2008;
Hennessy et al, 2010), or targeted agents such as PARP inhibitors
(PARPi) (Bryant et al, 2005; Farmer et al, 2005).
Cells deficient for BRCA1 or BRCA2 are highly sensitive to
PARP1 inhibitors (Bryant et al, 2005; Farmer et al, 2005), which are
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currently in use in clinical trials for cancer patients with BRCA1
and BRCA2 germline mutations (Gelmon et al, 2011;
O’Shaughnessy et al, 2011). Recent studies have suggested that
HR deficiency in epithelial ovarian cancer (EOC) is not solely due
to germline BRCA1 and BRCA2 mutations (Hennessy et al, 2010;
The Cancer Genome Atlas Network (TCGA), 2011; Byler Dann
et al, 2012). The Cancer Genome Atlas Research Network (2011)
reported a defect in at least one HR pathway gene in approximately
half of the B500 EOC in the data set.
Although BRCA1 and BRCA2 are thought of primarily as breast
and EOC susceptibility genes, mutations in these genes have been
reported in a number of other cancers (Friedenson, 2005).
Epigenetic silencing of BRCA1 has also been reported in nonsmall-cell lung cancer (Marsit et al, 2004), cervical cancer
(Narayan et al, 2003), and EOC (Wilcox et al, 2005). Several other
HR genes have also been reported to be mutated in other human
cancers (Cerbinskaite et al, 2011). In addition to the complexity of
types of alterations resulting in HR deficiency, each cancer type
would appear to have a unique spectrum of HR defects
(Cerbinskaite et al, 2011).
Defects in the HR pathway might result in specific structural
changes in DNA. Previously, chromosomal copy number (CN)
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MATERIALS AND METHODS
Additional information can be found in the Supplementary
Methods.

Ovarian tumour samples
Three independent human EOC cohorts were used. 1 : 152
unselected EOC samples from the Gynaecology Cancer Banks at
MD Anderson Cancer Centre (MDACC) and the University of
California San Francisco (UCSF). Magee-Womens Hospital of
UPMC (Pittsburgh, PA, USA) provided 2 : 53 late-stage serous
ovarian tumours and 3: 435 serous EOC samples for which
complete information was available from The Cancer Genome
Atlas Network web site (2011; http://tcga-data.nci.nih.gov/tcga/
dataAccessMatrix.htm?diseaseType=OV). All cohorts were obtained
under Institutional Review Board-approved protocols. Patient and
tumour characteristics are shown in Supplementary Table S1.
Varying numbers of samples were utilised in the assays described
(Supplementary Table S2).

Cell lines
Fifty-seven cancer cell lines were analysed (21 ovarian, 32 breast, 3
colon, 1 pancreatic) (see Supplementary Table S3). Two breast
cancer cell lines were obtained from DSMZ (Braunschweig,
Germany). The colon, pancreatic and remaining breast cancer cell
lines were obtained from ATCC (Manassas, VA, USA). Twenty-one
EOC cell lines were provided by the Gynaecology Cancer Bank at
MD Anderson Cancer Centre (MDACC).
Cell lines obtained from MD Anderson Cancer Centre were
validated by STR DNA fingerprinting using the AmpF_STR
Identifiler kit according to manufacturer’s instructions (Applied
Biosystems, Foster City, CA, USA; cat 4322288). The STR profiles
were compared with known ATCC fingerprints (ATCC.org), and to
the Cell Line Integrated Molecular Authentication database
(CLIMA) version 0.1.200808 (http://bioinformatics.istge.it/clima/)
(Nucleic Acids Research 37:D925-D932 PMCID: PMC2686526). The
STR profiles matched known DNA fingerprints or were unique.
Cell lines obtained from DSMZ and ATCC were authenticated
using STR DNA typing. Additional information can be found at the
DSMZ website (http://old.dsmz.de/human_and_animal_cell_lines/
main.php?content_id=86) and in Durkin and Reid (1998).

Extraction of genomic DNA and total RNA from frozen
tumours and cell lines
Ten micron frozen sections were cut and macrodissected. The
tissue was homogenised (TissueRuptor, Qiagen, Valencia, CA,
USA) after addition of QIAzol lysis reagent, following by RNA
isolation using a Qiagen miRNAeasy Mini Kit per the
& 2012 Cancer Research UK

manufacturers protocol. A QIAamp DNA Mini Kit (Qiagen) was
used to isolate DNA as per the manufacturer’s protocol with an
overnight lysis incubation at 56 oC and RNase A treatment.

BRCA1 and BRCA2 sequencing
BRCA1 and BRCA2 sequencing was performed as previously
described (Hennessy et al, 2010). Mutations identified were only
included in the analyses if classified as deleterious or suspected
deleterious based on previously described criteria (Beaudet and
Tsui, 1993).

Promoter methylation qPCR assays
The Methyl-Profiler DNA Methylation PCR Array System
(SABiosciences, Valencia, CA, USA) was used to quantify
methylation levels following the manufacturers recommended
protocol. Assay details are provided in Supplementary Table S4.

Methylation microarrays
Methylation data from TCGA were generated using the Infinium
HumanMethylation27 microarray (Illumina, San Diego, CA, USA).
Data were downloaded from the TCGA Network website and
analysed as described in the Supplemental Methods.

BRCA1 and cell cycle progression signature expression
assays
Assays were performed using TaqMan assays (Applied Biosystems)
on a Fluidigm (San Francisco, CA, USA) BioMark instrument.
Identification of samples with loss of BRCA1 expression The
method used is described in the Supplemental Methods. Assay
details are provided in Supplementary Table S5.

Affymetrix 500 K genechip arrays
The Affymetrix (Santa Clara, CA, USA) GeneChip Mapping NspI
or StyI microarrays were run according to the manufacturer’s
protocol.

Copy number and LOH analysis of SNP microarray data
Copy number and LOH analysis was performed using an algorithm
described in the Supplemental Methods. In addition to reconstructing CN and LOH profile, the algorithm estimates contamination with normal DNA.

Statistical analysis
The molecular assays used in the study are unreliable at high levels
of contamination of the tumour samples with normal tissue,
therefore samples with estimated contamination above 65% were
excluded from statistical analyses (the rationale for this cutoff is
explained in the Supplemental Results and in Supplemental
Figures S7, S8, and S9). P-values in this paper were calculated
using Kolmogorov–Smirnov test unless otherwise specified. A
comparison of the P-values obtained using the Kolmogorov–
Smirnov and Fisher tests is presented in the Supplemental
Methods.

RESULTS
Homologous recombination-deficient tumours
A tumour sample was considered HR deficient if it had a germline
or somatic mutation in BRCA1 or BRCA2, methylation, or low
British Journal of Cancer (2012) 107(10), 1776 – 1782
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changes have been reported to be associated with BRCA1 and
BRCA2 mutations (Stefansson et al, 2009; Holstege et al, 2010).
This study examines the association between genomic patterns of
loss of heterozygosity (LOH) and HR deficiency. Loss of
heterozygosity was examined in preference to CN because LOH
results in the irreversible loss of one of the parental alleles. In
contrast, CN gains are not necessarily permanent. Therefore, we
hypothesised that, if HR deficiency leaves a footprint of genomic
alterations, LOH may provide a more stable record of those
changes compared with CN variants. In this study we analysed
patterns of genome-wide LOH in three different EOC data sets
extensively characterised for BRCA1 and BRCA2 defects. An LOHbased score was developed, which is strongly associated with
functional defects in BRCA1 and BRCA2. This score also strongly
correlates with promoter methylation of RAD51C, a gene
implicated in the HR pathway.
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mRNA expression of BRCA1 and also demonstrated LOH for
BRCA1 or BRCA2. Methylation and expression analysis of BRCA2
did not identify any samples harbouring these defects. Thirty-one
of 152 samples from the first cohort were carriers of mutations in
BRCA1 and/or BRCA2, along with 14/53 from the second cohort
and 83/435 from the third cohort (two of which were excluded
from further analysis, see below). Mutations are summarised in
Supplementary Table S6.
The degree of methylation was measured for promoter CpG
islands of both BRCA1 and BRCA2. Methylation in multiple
samples was observed for BRCA1, but not BRCA2. Eleven of 126
samples from the first cohort (Supplementary Figure S1), 3 of 34
from the second cohort and 64 of 435 from the third cohort were
defined as HR deficient due to high levels of BRCA1 promoter
methylation. With the exception of one sample from the third
cohort, none of the samples with a methylated BRCA1 promoter
had concordant BRCA1 or BRCA2 mutations.
Mechanisms other than promoter methylation could result in
low mRNA expression of BRCA1 or BRCA2 that might also lead to
HR deficiency. BRCA1 and BRCA2 expression levels were
measured for 137 samples from the first cohort and 53 samples
from the second cohort. Expression of BRCA1 in 20 samples was
abnormally low. Only five samples with abnormally low expression
of BRCA1 were not flagged as HR deficient because of BRCA1
promoter methylation (Supplementary Figure S2). No abnormally
low expression was observed for BRCA2.
In this analysis, samples were only classified as BRCA deficient if
BRCA1 or BRCA2 was contained within a region of LOH and
carried a mutation, was methylated, or was expressed at low levels.
Two BRCA2-mutant samples that did not have LOH were not
considered HR deficient in our analysis. In total, in the three data
sets analysed (n ¼ 640) there were 211 samples with BRCA1 or
BRCA2 mutations, methylation, or low expression. In all but two of
these cases, both with BRCA2 mutations, there was homozygosity
at the affected gene due to LOH.

Correlation between samples with HR deficiency and LOH

0.5

At high levels of contamination of a tumour sample with normal
tissue the assays used in the study might be unreliable. Although
LOH reconstruction from SNP microarray data appear to be robust
up to 85% contamination and mutation detection results up to
90% contamination, methylation and RNA expression assays are
more sensitive to contamination and become unreliable above 65%
of contamination (Supplementary Results). Therefore, samples
with contamination above 65% have been excluded from the
analysis: 20 samples from the first cohort (two of them with BRCA1
mutations), 10 samples from the second cohort (one of them with a
BRCA1 mutation), and one sample from the third cohort.
The first cohort of samples was used as the ‘discovery’ cohort.
LOH regions on chromosome 17 were excluded from the analysis,
because LOH was observed over this chromosome in almost all
samples. We checked for correlation between HR deficiency and
the number of short LOH regions (o15 Mb), the number of long
LOH regions (415 Mb but less than the whole chromosome), and
the number of LOH regions covering whole chromosomes. The
value of 15 Mb was selected somewhat arbitrarily, but further
analysis showed that the exact value of this cut-off does not have
significant impact on the results (Supplementary Figure S4). There
was no significant correlation between the number of short LOH
regions and HR deficiency. The number of LOH regions covering
the whole chromosome was significantly greater in tumours
with intact BRCA1 or BRCA2 (P ¼ 4  10  5) (Supplementary
Figure S3a). The number of long LOH regions (415 Mb but less
than the whole chromosome) was significantly higher in tumours
with deficient BRCA1 or BRCA2 (P ¼ 10  11) (Figure 2A). From these
samples, we determined a homologous recombination deficiency
(HRD) score defined as the number of LOH regions 415 Mb, but
less than a whole chromosome in length, within a tumour genome.
The second and third cohorts were used to validate the results
obtained for the first cohort. Homologous recombination deficiency was not correlated with the number of LOH regions
covering whole chromosomes in the second cohort, possibly due to
low sample number, but this observation was confirmed in the
third cohort (P ¼ 3  10  11) (Supplementary Figure S3b). Highly
significant correlation was observed between HRD score and HR
deficiency for both cohorts (P ¼ 10  5 and P ¼ 10  29, respectively)
with HRD score being distinctly reduced among ovarian tumours
with intact BRCA1 and BRCA2 (Figures 2B and C).

0.4

Alterations in RAD51C and other HR pathway genes

Distribution of lengths of LOH regions
SNP analysis was used to determine the distribution of lengths of
LOH regions throughout the genome. The lengths of LOH regions
adjusted to the length of chromosome arm on which the LOH
regions were observed are shown in Figure 1. Three distinct
features were observed in this distribution. First, there are many

0.6
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Fraction of LOH regions

short LOH regions (o15 Mb). Second, there is a long flat tail of
LOH regions up to the length of a single chromosome arm with few
LOH regions covering more than one chromosome arm but less
than the whole chromosome. Finally, there is a high peak
corresponding to LOH over the whole chromosome.

0.3
0.2
0.1
0

0

0.2

0.4

0.6 0.8
1
1.2 1.4 1.6
Relative length of LOH region

1.8

2

Figure 1 Fraction of lengths of LOH regions vs length of these regions
adjusted to the length of chromosome arm. Chromosomes 13, 14, 15, and
22 were excluded because SNPs are not available for the p arms of these
chromosomes. The largest adjusted value of 2 corresponds to LOH over
the entire chromosome.
British Journal of Cancer (2012) 107(10), 1776 – 1782

Published data suggest that BRCA1 and BRCA2 are the primary
genes responsible for HR deficiency in EOC (TCGA, 2011).
However, many other genes may also be important, such as
RAD51C and RAD51D both of which have been recently been
implicated as predisposition genes for EOC (Meindl et al, 2010;
Loveday et al, 2011). In the TCGA data set there were no RAD51C
or RAD51D mutations reported; however, 11/435 samples had
methylation of the RAD51C promoter. In addition, the degree of
methylation was measured for promoter CpG islands of eight genes
involved in the HR pathway in addition to BRCA1 and BRCA2
(Supplementary Table S4) in the first cohort. Only RAD51C had
high levels of promoter methylation in 3 of 89 samples. All samples
positive for RAD51C methylation from both cohorts were
homozygous at the RAD51C locus because of LOH. To test
whether the HRD score is elevated in samples with RAD51C
promoter methylation samples from both cohorts were compared
& 2012 Cancer Research UK
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Figure 2 Homologous recombination deficiency score in tumour samples. The number of long LOH regions is shown on the x axis. Blue circles: BRCA1or BRCA2-deficient samples. Red circles: BRCA1- and BRCA2-intact samples. The combined area under the blue and red circles is the same. This normalisation
is used only to facilitate visualisation of the circles. The size of each individual circle is proportional to the number of samples with the corresponding number
of LOH regions. (A) Homologous recombination deficiency score for the first cohort (44 of 132 samples were BRCA1 or BRCA2 deficient). (B)
Homologous recombination deficiency score for the second cohort (18 of 43 samples were BRCA1 or BRCA2 deficient). (C) Homologous recombination
deficiency score for the third cohort (146 of 434 samples were BRCA1 or BRCA2 deficient). (D) Homologous recombination deficiency score for the
combined data from all three cohorts. Row A: 221 samples with either BRCA1, or BRCA2, or RAD51C deficient genes; B: 80 BRCA1 mutants (a BRCA1
mutant with a BRCA2 mutation, a BRCA1 mutant with a methylated BRCA1 promoter, and a BRCA1 mutant with a methylated RAD51C promoter were
excluded from this plot); C: 43 BRCA2 mutants (a BRCA2 mutant with a BRCA1 mutation was excluded from this plot); D: 82 samples with low expression or
methylation of BRCA1 (a sample with a methylated BRCA1 promoter and a BRCA1 mutation was excluded from this plot); E: 13 samples with methylation of
RAD51C (a sample with a methylated RAD51C promoter and a BRCA1 mutation was excluded from this plot). Red circles: 388 samples with BRCA1, BRCA2,
and RAD51C intact genes.
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nonsense mutation). As deactivation of both alleles is needed to
lose function of a tumour suppressor, 12 of these 13 samples are
expected to have intact HR. Not surprisingly, the HRD score was
not elevated in the majority of these samples (data not shown).

Analysis of combined data
Correlation between the HRD score and HR deficiency (defined as
deficiency of BRCA1, BRCA2, or RAD51C) for all three cohorts is
presented in Figure 2D. A highly significant association is seen
(P ¼ 2  10  48) (Table 1).
An important question is whether the distribution of HRD
scores is the same for HR deficiency because of different genomic
loci. To answer this, the distributions of HRD scores for BRCA1-,
BRCA2-, and RAD51C-deficient tumours were analysed separately
(Supplementary Figure S6). A significant difference was observed
(P ¼ 6  10  5) with BRCA1-deficient samples a having higher
average HRD score (16.2; s.d. ¼ 4.3) than BRCA2-deficient samples
(13.0; s.d. ¼ 3.9). The differences in HRD scores between either
BRCA1 or BRCA2 and RAD51C (14.5; s.d. ¼ 5.1) were not
significant.
To determine whether mutations in BRCA1 and BRCA2 were
germline or somatic, normal tissue was analysed when available. A
subset of normal samples from the first and second cohorts, and all
samples from the third cohort were available. There was no
significant difference in the distributions of HRD scores for either
BRCA1 or BRCA2 deficiency between germline and somatic
mutations, or between mutations and either methylation or low
expression (Supplementary Figure S5).
British Journal of Cancer (2012) 107(10), 1776 – 1782
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with BRCA intact samples without RAD51C methylation. Consistent with our observations for BRCA1 and BRCA2 genes, HRD
score was significantly higher (P ¼ 0.0003) among samples with
RAD51C methylation.
It has been reported that PTEN-deficient tumour cells are
sensitive to PARPi, and suggested that deficiency in PTEN results
in HR pathway defects (Mendes-Pereira et al, 2009). Copy number
analysis revealed 2/132 samples from the first data set (HRD
scores ¼ 11 and 21) and 0/43 samples from the second data set had
homozygous deletions of PTEN. Both of the PTEN-deficient
samples also had defects in either BRCA1 or BRCA2. In the third
data set 11/435 samples had homozygous deletions of PTEN, and
their HRD scores ranged from 9–22. An additional 3/435 samples
had likely deleterious mutations (nonsense, frameshift, or splicesite mutations) in PTEN with homozygosity at the PTEN locus
because of LOH (HRD scores ¼ 8, 16, 24). Five of these samples
had defects in BRCA1, BRCA2, or RAD51C. The remaining nine
samples had a significantly elevated (P ¼ 0.004) average HRD score
of 14.5 (range 8–24) consistent with PTEN having a role in
homologous recombination.
In the third cohort presumed deleterious mutations and
methylation of HR pathway genes have been reported (TCGA,
2011). The mutations were examined and the analysis was limited
to defects with a high likelihood of being deleterious (for example,
nonsense and frameshift mutations), resulting in a total of eight
deleterious mutations in six genes (ATM, ATR, FANCA, FANCD2,
FANCM, and PALB2) not discussed above. An additional five
samples had methylation of HR pathway genes. Loss of heterozygosity was detected in only 1 of the 13 samples (a FANCM
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Table 1

Average of HRD score for BRCA1 and BRCA2 deficient and intact tumours and corresponding P-values
HR deficient (BRCA1
and BRCA2)

HR intact (BRCA1
and BRCA2)

HR deficient (BRCA1, BRCA2,
and RAD51C)

HR intact (BRCA1, BRCA2,
and RAD51C)

First cohort

16.1 (s.d. ¼ 4.5)

7.9 (s.d. ¼ 6.1)

16.5 (s.d. ¼ 4.7)

7.6 (s.d. ¼ 5.6)

Second cohort

15.5 (s.d. ¼ 4.5)

6.4 (s.d. ¼ 5.2)

15.5 (s.d. ¼ 4.5)

Third cohort

15.3 (s.d. ¼ 4.3)

8.8 (s.d. ¼ 5.0)

15.1 (s.d. ¼ 4.3)

Combined data for three cohorts

15.5 (s.d. ¼ 4.4)
8.4 (s.d. ¼ 5.3)
P ¼ 7  10  45

15.4 (s.d. ¼ 4.4)

Cancer cell lines

19.9 (s.d. ¼ 5.0)

19.9 (s.d. ¼ 5.0)

P ¼ 10  11
P ¼ 10  5
P ¼ 10  29

8.0 (s.d. ¼ 5.5)
P ¼ 0.0001

P ¼ 10  12
P ¼ 10  5
P ¼ 3  10  32
P ¼ 2  10  48

6.4 (s.d. ¼ 5.2)
8.6 (s.d. ¼ 5.0)
8.2 (s.d. ¼ 5.2)
8.0 (s.d. ¼ 5.5)

P ¼ 0.0001

Abbreviations: HR ¼ homologous recombination; HRD ¼ homologous recombination deficiency.
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Figure 3 Comparison of HRD scores in cancer cell lines. Red circles: cell
lines with intact BRCA1 or BRCA2. (A) 28 non-ovarian cell lines; (B) 16
ovarian cell lines. Green circles: six carriers of heterozygous mutations in
either BRCA1 or BRCA2. Violet circles: one carrier of a homozygous
mutation with reversion in BRCA1. Blue circles: six carriers of homozygous
mutations in either BRCA1 or BRCA2 or with methylated BRCA1. The
combined area under the green, red, blue and violet circles is the same. The
size of each individual circle is proportional to the number of samples with
the corresponding number of LOH regions.

Homologous recombination deficiency score in BRCA1and BRCA2-deficient cell lines
Unselected breast (n ¼ 32) and ovarian (n ¼ 21) cell lines were
obtained from multiple sources and screened for mutations in
BRCA1 or BRCA2. In addition three colon and one pancreatic cell
line from NCI60 were analysed. Of these 57 cell lines, six either
carried homozygous deleterious mutations or had methylation of
the BRCA1 promoter and LOH at BRCA1, one had a homozygous
mutation with an apparent functional reversion, and six carried
heterozygous mutations (mutations are described in Supplementary
Table S7). Figure 3 shows the distributions of HRD scores for
these three groups of mutants, as well as for samples that do not
carry BRCA mutations. The distributions of HRD scores among
ovarian tumours and cancer cell lines without BRCA defects were
not significantly different. The distribution of HRD scores among
cancer cell lines with heterozygous mutations is similar to cancer
cell lines without BRCA defects, presumably because cells become
HR deficient only when both copies of BRCA1 or BRCA2 are nonfunctional. For cancer cell lines with functional loss of both
British Journal of Cancer (2012) 107(10), 1776 – 1782
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Figure 4 Kaplan–Meier plot of OS post surgery for HRD score split at
it’s median. These data were generated using 507 samples from the TCGA
data set for which copy number data and survival information were
available. Median OS for samples with high and low HRD score were 1499
(95% CI ¼ (1355–1769)) and 1163 (95% CI ¼ (1081–1354)) days,
respectively. The P-value was calculated using Cox model.

copies of either BRCA1 or BRCA2, higher HRD scores are
observed, similar to HRD scores observed for ovarian tumours
with BRCA1-, BRCA2-, or RAD51C-deficient genes. The HRD
score is also high for the cancer cell line with reversion of a
BRCA1 mutation. The difference of the distribution of HRD
scores in either wild-type or heterozygous mutant cell lines, and
the distribution of HRD scores in cell lines with either
homozygous mutations (with or without reversion) or methylation of the BRCA1 promoter is highly significant (P ¼ 0.0001).
Importantly, there is significant correlation between HRD score
and BRCA1 and BRCA2 deficiency even after excluding EOC cell
lines from the data set (P ¼ 0.01), suggesting that association of
HRD score with HR deficiency is not restricted to EOC.

Correlation between HR deficiency and overall survival
(OS) and progression free survival (PFS)
Correlation was not detected between HRD score and either OS or
PFS for the first two cohorts, possibly because of cohort size.
Significant correlation was observed between PFS (P ¼ 0.03) and
OS (P ¼ 6  10  5) for the third cohort with improved survival for
patients with higher HRD scores (Figure 4).
& 2012 Cancer Research UK
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This study reports the development of a DNA-based HRD score
based on genome-wide LOH analysis of ovarian tumours
combined with comprehensive profiling of BRCA1 and BRCA2
defects. The HRD score is strongly associated with the integrity of
homologous recombination, as measured by BRCA1, BRCA2, and
RAD51C defects. The correlation of HRD score and HR deficiency
was validated in two independent EOC data sets, as well as breast
and pancreatic cancer cell lines.
The initial hypothesis was that regions of LOH of different
length might appear in the cancer genome through different pathways, thus tumours with HR deficiency might manifest a specific
pattern of LOH. In this study, we identified an intermediate class of
LOH sizes 415 Mb but less than a whole chromosome that was
highly positively correlated with defective HR genes suggesting
that most if not all, of this type of LOH class exists, because it
incorporates double-stranded DNA breaks as part of its genesis
and requires repair by HR. In contrast, LOH at the whole
chromosome level is significantly less frequent in HR-deficient
tumours. One possible explanation is that LOH at the whole
chromosome level frequently originates through an alternative
mechanism that does not involve double-stranded DNA breaks.
In addition to BRCA1 and BRCA2 defects, RAD51C promoter
methylation was observed in ovarian tumours. High HRD score
was significantly associated with RAD51C deficiency in two data
sets. Elevated HRD scores were also seen in PTEN-deficient
tumours, consistent with reports that PTEN-defective tumour cell
are HR defective (Mendes-Pereira et al, 2009). Only one additional
HR gene mutation was confirmed in the three data sets, a nonsense
mutation in FANCM with LOH resulting in loss of the second
allele. The HRD score associated with the FANCM mutation
(TCGA, 2011) is within the range of the normal distribution for
samples with elevated HRD score.
Among tumours with apparently intact BRCA1, BRCA2, and
RAD51C, a substantial fraction of the samples have an elevated
HRD score. Two possible explanations are that there is a
substantial rate of defects in other genes in the HR pathway in
many of these samples, or that the HRD score is non-specific.
Published studies have demonstrated that secondary reversion
mutations that restore BRCA2 function can arise in BRCA2
mutant cell lines after exposure to platinum agents (Edwards et al,
2008; Sakai et al, 2008, 2009). Norquist et al (2011) observed
similar findings in vivo, with B28% of recurrent tumours having
a secondary mutation that restored BRCA1 or BRCA2 function.
Reversion mutations were observed primarily in individuals with
prior exposure to platinum agents and were predictive of
resistance to platinum. As the HRD score results from cumulative
defects occurring in the genome of the tumour, it should not be
sensitive to reversion mutations. Post-treatment samples were not
available from the tumours used in this study, however, the
limited data obtained from cell lines with reversion mutations is
consistent with this hypothesis. It should be noted that the
insensitivity of the HRD score to reversion mutations would affect

few tumours in the neoadjuvant or adjuvant setting (Norquist
et al, 2011).
Recently, Birkbak et al (2012) have reported a telomeric allelic
imbalance score, which predicted pathological complete response
to cisplatin treatment in triple negative breast cancer patients.
Although the score itself is very different from the score we have
identified, which is based solely on LOH, future plans include
investigating how well correlated the HRD and TAI scores are with
one another. In addition, we would like to determine whether the
TAI score is associated with BRCA1, BRCA2, and RAD51C defects
in our cohorts similar to the HRD score.
Current studies are focused on evaluating the ability of the HRD
score to identify BRCA-deficient tumours in breast and pancreatic
cancer data sets. If the HRD score is validated as a surrogate
marker for HR deficiency, regardless of mechanism, it could be
used as a quick and reliable assay for tumour stratification. In
addition, studies are underway to investigate the ability of this
score to predict response to both platinum agents and PARPi. The
current data suggest that a high HRD score is highly correlated
with HR deficiency, and that this score could be utilised to identify
patients with high likelihood of responding to DNA damaging
agents and PARPi. Such a test would have clinical utility in breast
and EOC, and could conceivably be used to expand the use of
PARPi and platinum salts to other cancers.
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